Physician profile
Tejalkumar Patel
NPI 1730588005
$2,011.22
in general payments reported to CMS, 2019-2025
19 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $332 · 2022: $363 · 2023: $718 · 2024: $335 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $407.13 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $372.21 | 2021-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $144.94 | 2022-2023 | |
| Mylan Specialty L.P. | $124.98 | 2024 | Yupelri |
| Lilly USA, LLC | $122.70 | 2022-2024 | Zepbound, Mounjaro |
| Gilead Sciences, INC. | $112.39 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $112.16 | 2024 | Camzyos |
| Amgen INC. | $100.96 | 2025 | Evenity, Uplizna |
| Dexcom, INC. | $94.91 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Indivior INC. | $87.18 | 2025 | Sublocade |
| Exact Sciences Corporation | $85.12 | 2023-2025 | Cologuard Collection Kit |
| Alkermes, INC. | $78.51 | 2022 | |
| Novo Nordisk INC | $47.62 | 2023-2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $42.07 | 2025 | |
| Astellas Pharma US INC | $19.39 | 2023 | Veozah |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $16.93 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.65 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $13.28 | 2024 | Airsupra |
| Pfizer INC. | $13.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejalkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.